161 related articles for article (PubMed ID: 33126611)
21. Comparative Genomics for the Elucidation of Multidrug Resistance in Candida lusitaniae.
Kannan A; Asner SA; Trachsel E; Kelly S; Parker J; Sanglard D
mBio; 2019 Dec; 10(6):. PubMed ID: 31874914
[TBL] [Abstract][Full Text] [Related]
22. Amphotericin B-copper(II) complex as a potential agent with higher antifungal activity against Candida albicans.
Chudzik B; Tracz IB; Czernel G; Fiołka MJ; Borsuk G; Gagoś M
Eur J Pharm Sci; 2013 Aug; 49(5):850-7. PubMed ID: 23791641
[TBL] [Abstract][Full Text] [Related]
23. Comparative analysis of amphotericin B lipid complex and liposomal amphotericin B kinetics of lung accumulation and fungal clearance in a murine model of acute invasive pulmonary aspergillosis.
Lewis RE; Liao G; Hou J; Chamilos G; Prince RA; Kontoyiannis DP
Antimicrob Agents Chemother; 2007 Apr; 51(4):1253-8. PubMed ID: 17261624
[TBL] [Abstract][Full Text] [Related]
24. Efficacy of deoxycholate amphotericin B and unilamellar liposomal amphotericin B in prophylaxis of experimental Aspergillus fumigatus endocarditis.
Mylonakis E; Chalevelakis G; Saroglou G; Danias P; Argyropoulou AD; Paniara O; Raptis SA
Mayo Clin Proc; 1997 Nov; 72(11):1022-7. PubMed ID: 9374975
[TBL] [Abstract][Full Text] [Related]
25. Aspergillus species collected from environmental air samples in Portugal-molecular identification, antifungal susceptibility and sequencing of cyp51A gene on A. fumigatus sensu stricto itraconazole resistant.
Monteiro C; Pinheiro D; Maia M; Faria MA; Lameiras C; Pinto E
J Appl Microbiol; 2019 Apr; 126(4):1140-1148. PubMed ID: 30735287
[TBL] [Abstract][Full Text] [Related]
26. In vitro and in vivo activities of NS-718, a new lipid nanosphere incorporating amphotericin B, against Aspergillus fumigatus.
Otsubo T; Maesaki S; Hossain MA; Yamamoto Y; Tomono K; Tashiro T; Seki J; Tomii Y; Sonoke S; Kohno S
Antimicrob Agents Chemother; 1999 Mar; 43(3):471-5. PubMed ID: 10049253
[TBL] [Abstract][Full Text] [Related]
27. In vitro activity of the echinocandin antifungal agent LY303,366 in comparison with itraconazole and amphotericin B against Aspergillus spp.
Oakley KL; Moore CB; Denning DW
Antimicrob Agents Chemother; 1998 Oct; 42(10):2726-30. PubMed ID: 9756785
[TBL] [Abstract][Full Text] [Related]
28. Budget impact analysis of liposomal amphotericin B and amphotericin B lipid complex in the treatment of invasive fungal infections in the United States.
Yang H; Chaudhari P; Zhou ZY; Wu EQ; Patel C; Horn DL
Appl Health Econ Health Policy; 2014 Feb; 12(1):85-93. PubMed ID: 24385260
[TBL] [Abstract][Full Text] [Related]
29.
Siopi M; Mouton JW; Pournaras S; Meletiadis J
Antimicrob Agents Chemother; 2019 Jun; 63(6):. PubMed ID: 30962332
[No Abstract] [Full Text] [Related]
30. Molecular identification and amphotericin B susceptibility testing of clinical isolates of Aspergillus from 11 hospitals in Korea.
Heo MS; Shin JH; Choi MJ; Park YJ; Lee HS; Koo SH; Lee WG; Kim SH; Shin MG; Suh SP; Ryang DW
Ann Lab Med; 2015 Nov; 35(6):602-10. PubMed ID: 26354348
[TBL] [Abstract][Full Text] [Related]
31. Aspergillus terreus: Novel lessons learned on amphotericin B resistance.
Posch W; Blatzer M; Wilflingseder D; Lass-Flörl C
Med Mycol; 2018 Apr; 56(suppl_1):73-82. PubMed ID: 29538736
[TBL] [Abstract][Full Text] [Related]
32. International expert opinion on the management of infection caused by azole-resistant Aspergillus fumigatus.
Verweij PE; Ananda-Rajah M; Andes D; Arendrup MC; Brüggemann RJ; Chowdhary A; Cornely OA; Denning DW; Groll AH; Izumikawa K; Kullberg BJ; Lagrou K; Maertens J; Meis JF; Newton P; Page I; Seyedmousavi S; Sheppard DC; Viscoli C; Warris A; Donnelly JP
Drug Resist Updat; 2015; 21-22():30-40. PubMed ID: 26282594
[TBL] [Abstract][Full Text] [Related]
33. Protective and antifungal properties of Nanodisk-Amphotericin B over commercially available Amphotericin B.
Cho DY; Hoffman KJ; Gill GS; Lim DJ; Skinner D; Mackey C; Rowe SM; Woodworth BA
World J Otorhinolaryngol Head Neck Surg; 2017 Mar; 3(1):2-8. PubMed ID: 29204573
[TBL] [Abstract][Full Text] [Related]
34. A comparative study of the in vitro susceptibilities of clinical and laboratory-selected resistant isolates of Aspergillus spp. to amphotericin B, itraconazole, voriconazole and posaconazole (SCH 56592).
Manavathu EK; Cutright JL; Loebenberg D; Chandrasekar PH
J Antimicrob Chemother; 2000 Aug; 46(2):229-34. PubMed ID: 10933645
[TBL] [Abstract][Full Text] [Related]
35. Surveillance for azoles resistance in Aspergillus spp. highlights a high number of amphotericin B-resistant isolates.
Reichert-Lima F; Lyra L; Pontes L; Moretti ML; Pham CD; Lockhart SR; Schreiber AZ
Mycoses; 2018 Jun; 61(6):360-365. PubMed ID: 29468746
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of antimicrobial agents using an experimental pulmonary superinfection model with Aspergillus fumigatus and Pseudomonas aeruginosain leukopenic mice.
Mitsuyama J; Kizawa K; Minami S; Watanabe Y; Yamaguchi K
J Infect Chemother; 2003 Jun; 9(2):144-50. PubMed ID: 12825113
[TBL] [Abstract][Full Text] [Related]
37. Amphotericin B-copper(II) complex shows improved therapeutic index in vitro.
Chudzik B; Czernel G; Miaskowski A; Gagoś M
Eur J Pharm Sci; 2017 Jan; 97():9-21. PubMed ID: 27816628
[TBL] [Abstract][Full Text] [Related]
38. A comparative study of fungicidal activities of voriconazole and amphotericin B against hyphae of Aspergillus fumigatus.
Krishnan S; Manavathu EK; Chandrasekar PH
J Antimicrob Chemother; 2005 Jun; 55(6):914-20. PubMed ID: 15824093
[TBL] [Abstract][Full Text] [Related]
39. Insight into the Significance of Aspergillus fumigatus cyp51A Polymorphisms.
Garcia-Rubio R; Alcazar-Fuoli L; Monteiro MC; Monzon S; Cuesta I; Pelaez T; Mellado E
Antimicrob Agents Chemother; 2018 Jun; 62(6):. PubMed ID: 29632011
[TBL] [Abstract][Full Text] [Related]
40. The Role of Signaling via Aqueous Pore Formation in Resistance Responses to Amphotericin B.
Cohen BE
Antimicrob Agents Chemother; 2016 Sep; 60(9):5122-9. PubMed ID: 27381391
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
